Related Experiment Video
Updated: May 16, 2026
06:46
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes
1Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
Diabetic Medicine : a Journal of the British Diabetic Association
|November 20, 2012
Summary
Serum apolipoprotein M (apoM) is lower in hepatocyte nuclear factor 1 alpha-maturity onset diabetes of the young (HNF1A-MODY) than in Type 1 diabetes. ApoM shows potential as a biomarker for diagnosing HNF1A-MODY.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Biomarker Discovery
Background:
- Maturity-onset diabetes of the young (MODY) is often misdiagnosed, necessitating reliable biomarkers for early identification.
- Hepatocyte nuclear factor 1 alpha (HNF1A)-MODY is a genetic subtype of diabetes.
- Apolipoprotein M (apoM) has been proposed as a potential biomarker for HNF1A-MODY, but previous studies yielded conflicting results.
Purpose of the Study:
- To evaluate the diagnostic utility of serum apolipoprotein M (apoM) as a biomarker for HNF1A-MODY.
- To compare apoM levels in HNF1A-MODY patients with those in Type 1 diabetes, Type 2 diabetes, and healthy controls.
- To assess the discriminative accuracy of apoM and the apoM/HDL ratio in differentiating HNF1A-MODY from other diabetes types.
Main Methods:
- Serum apoM concentrations were measured using a highly specific and sensitive ELISA.
- Study participants included individuals with HNF1A-MODY (n=69), Type 1 diabetes (n=50), Type 2 diabetes (n=120), and healthy controls (n=100).
- The discriminative accuracy of apoM and the apoM/HDL ratio was evaluated using the C-statistic.
Main Results:
- Serum apoM levels were significantly lower in HNF1A-MODY patients compared to Type 1 diabetes and healthy controls (P < 10⁻¹⁸).
- No significant difference in apoM levels was observed between HNF1A-MODY and Type 2 diabetes patients (P = 0.13).
- ApoM demonstrated high discriminative accuracy between HNF1A-MODY and Type 1 diabetes (C-statistic = 0.91). The apoM/HDL ratio showed lower discriminative performance.
Conclusions:
- Serum apoM levels are indeed lower in HNF1A-MODY compared to healthy controls, confirming previous findings.
- Serum apoM shows good potential for discriminating HNF1A-MODY from Type 1 diabetes.
- Further research is warranted to explore the clinical utility of apoM in diabetes diagnostics.
Related Concept Videos
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...